check_circleStudy Completed

pulmonary arterial hypertension

Comparative PK PD Study in PAH patients (Fox vs. I-Neb)

Trial purpose

Administration of iloprost aerosol comparing two nebulizers: FOX and I-Neb

Key Participants Requirements

Sex

Both

Age

18 - N/A

Trial summary

Enrollment Goal
27
Trial Dates
March 2014 - September 2017
Phase
Phase 1/Phase 2
Could I Receive a placebo
No
Products
Ventavis (Iloprost, BAYQ6256)
Accepts Healthy Volunteer
No

Where to participate

StatusInstitutionLocation
Completed
Gießen, 35392, Germany
Completed
Hamburg, 20246, Germany
Completed
Köln, 50924, Germany
Completed
Würzburg, 97067, Germany
Completed
München, 80639, Germany
Completed
Graz, 8036, Austria

Primary Outcome

  • The proportion of patients with a meaningful maximum increase (i.e. >=25%) in heart rate AND/OR a meaningful maximum decrease (i.e. >=20%) in systolic blood pressure within the 30 minutes after the start of inhalation
    date_rangeTime Frame:
    multiple measurements within 30 minutes after iloprost inhalation
    enhanced_encryption
    Safety Issue:
    Yes

Secondary Outcome

  • Maximum change in systolic, diastolic and mean arterial blood pressure
    date_rangeTime Frame:
    From baseline to multiple BP measurements within 2 hours after iloprost inhalation
    enhanced_encryption
    Safety Issue:
    Yes
  • Maximum change in heart rate within the 30 minutes following inhalation
    date_rangeTime Frame:
    From baseline to multiple HR measurements within 30 minutes after iloprost inhalation
    enhanced_encryption
    Safety Issue:
    Yes
  • Maximum change in oxygen saturation within the 30 minutes following inhalation using finger pulse oxymetry
    date_rangeTime Frame:
    From baseline to multiple measurements within 30 minutes after iloprost inhalation
    enhanced_encryption
    Safety Issue:
    Yes
  • AUC (area under the plasma concentration curve of BAYQ6256 from zero to infinity)
    date_rangeTime Frame:
    Multiple timepoints up to 1 hour
    enhanced_encryption
    Safety Issue:
    No
  • Maximum observed drug concentration in plasma after single dose administration
    date_rangeTime Frame:
    Multiple blood sampling within 60 minutes after Ventavis inhalation and subsequent iloprost bioanalytics
    enhanced_encryption
    Safety Issue:
    No
  • Time to reach maximum drug observed concentration in plasma after single dose
    date_rangeTime Frame:
    Multiple blood sampling within 60 minutes after Ventavis inhalation and subsequent iloprost bioanalytics
    enhanced_encryption
    Safety Issue:
    No
  • half-life (associated with terminal slope)
    date_rangeTime Frame:
    Multiple blood sampling within 60 minutes after Ventavis inhalation and subsequent iloprost bioanalytics
    enhanced_encryption
    Safety Issue:
    No

Trial design

A multi-center, open-label, randomized cross-over study to compare the acute tolerability and pharmacokinetics of BAYQ6256 (iloprost; Ventavis) inhalation using the I-Neb nebulizer and the FOX nebulizer in patients with pulmonary arterial hypertension
Trial Type
Interventional
Intervention Type
Drug
Trial Purpose
Treatment
Allocation
Randomized
Blinding
Open Label
Assignment
Crossover Assignment
Trial Arms
2